All In Biotech

Drug Trial Radar · NCT06736990

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

A Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jun 20, 2025

Primary completion

Nov 2026

Study completion Feb 2027

Sponsor

Lead sponsor
Calluna Pharma ASIndustry
Sponsor type
Industry
First posted
Dec 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • CAL101Drug

    Intravenous infusions of CAL101 every 4 weeks over 24 weeks

  • PlaceboDrug

    Intravenous infusions of placebo every 4 weeks over 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in forced vital capacity (FVC) compared to placeboTime frame: 28 weeks

Locations

54 sites in 11 countries. Site status is shown where the registry gives one.

  • Keck School of Medicine at USC

    Los Angeles, California

  • National Jewish Health

    Denver, Colorado

  • Y & L Advance Health Care, Inc. d/b/a Elite Clinical Research

    Miami, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Pulmonix, LLC

    Greensboro, North Carolina

  • Southeastern Research Center

    Winston-Salem, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • University of Utah Health

    Salt Lake City, Utah

  • Aarhus University Hospital

    Aarhus, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Odense University Hospital

    Odense, Denmark

  • AP-HP Hopital Avicenne

    Bobigny, France

  • AP-HP Hopital Europeen Georges Pompidou

    Paris, France

  • CHU Rennes - Hopital Pontchaillou

    Rennes, France

  • CHU de Toulouse - Hopital Larrey

    Toulouse, France

  • CHRU de Tours - Hôpital Bretonneau

    Tours, France

  • Azienda Ospedaliero-Universitaria di Modena

    Modena, Italy

  • AORN - Ospedali dei Colli - Ospedale V. Monaldi

    Naples, Italy

  • Istituto Clinico Humanitas - Pneumologia 1

    Rozzano, Italy

  • Azienda Ospedale - Università Padova

    Padova, PD, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Roma, RM, Italy

  • Azienda Ospedaliero Universitaria Senese

    Siena, SI, Italy

  • Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale di Cattinara

    Trieste, TS, Italy

  • Erasmus MC

    Rotterdam, South Holland, Netherlands

  • St. Antonius Ziekenhuis - Locatie Nieuwegein

    Nieuwegein, Utrecht, Netherlands

  • Haukeland University Hospital

    Bergen, Norway

  • Akershus University Hospital

    Lørenskog, Norway

  • Oslo University Hospital, Rikshospitalet

    Oslo, Norway

  • Institutul de Pneumoftiziologie Marius Nasta

    Bucharest, Romania

  • Spitalul Clinic de Pneumoftiziologie ''Leon Daniello''

    Cluj-Napoca, Cluj, Romania

  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie ''Victor Babes'' Craiova

    Craiova, Dolj, Romania

  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie dr. Victor Babes Timisoara

    Timișoara, Timiș County, Romania

  • Seoul National University Bundang Hospital

    Gyeonggi-do, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Ajou University Hospital

    Suwon, Gyeonggi-do, South Korea

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.